Get the Stockscreener App
0.0111
0.00%
0.00
After Hours:
.01
-0.0011
-9.91%
Virpax Pharmaceuticals Inc stock is traded at $0.0111, with a volume of 629.
It is up +0.00% in the last 24 hours and down -47.14% over the past month.
See More
Previous Close:
$0.0111
Open:
$0.0111
24h Volume:
629
Relative Volume:
1.66
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-13.24M
P/E Ratio:
-0.00126
EPS:
-8.83
Net Cash Flow:
$-16.85M
1W Performance:
+0.00%
1M Performance:
-47.14%
6M Performance:
-95.41%
1Y Performance:
-99.74%
1-Day Range:
$0.0111
$0.0111
1-Week Range:
$0.0111
$0.0111
52-Week Range:
$0.01
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare VRPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.0111 | 0 | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.68 | 121.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.44 | 78.94B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
847.72 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.79 | 46.18B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Virpax Pharmaceuticals to conduct reverse stock split - Intellectia AI
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
EBITDA per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
Virpax Pharmaceuticals Inc. (VRPX) Stock Price | Live Quotes & Charts | EXPM - StocksToTrade
Tangible book value per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
CapEx per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
RTW Biotech invests USD5.9 million in Yarrow Bioscience funding round - marketscreener.com
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Stocks advance as Nvidia earnings light up global markets - marketscreener.com
Wall Street opens higher as Nvidia test looms - marketscreener.com
Analyzing Virpax Pharmaceuticals (NASDAQ:VRPX) and IMV (OTCMKTS:IMVIQ) - Defense World
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Jones Expects Nasdaq to Climb Higher, Lower Rates - marketscreener.com
Virpax Pharmaceuticals, Inc.Common Stock (NQ: - FinancialContent
TNF Pharmaceuticals Regains Compliance With Nasdaq Listing Requirement - marketscreener.com
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Head-To-Head Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) vs. Evotec (OTCMKTS:EVTCY) - Defense World
Virpax reports positive study results for pain management drug - MSN
Top Nanotechnology Stocks To Follow Today – August 25th - Defense World
Hookipa Pharma to Voluntarily Delist From Nasdaq - marketscreener.com
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Top Nanotechnology Stocks To Follow NowJuly 10th - MarketBeat
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
VRPX Stock Price and Chart — OTC:VRPX - TradingView
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes - TipRanks
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split By Investing.com - Investing.com UK
Virpax Reports on Progress of Envelta™ - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
Virpax receives positive Probudur™ results for dose range study - TradingView
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com South Africa
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Virpax Pharmaceuticals Announces Positive Results from U.S. Army Study on Probudur™ - Kalkine Media
Star TribuneVirpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - FinancialContent
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - FinancialContent
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Virpax Pharmaceuticals names new board director - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
Dow Theory LettersSpartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - FinancialContent
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug - Stock Titan
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy, Price Target is $173 - marketscreener.com
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com
Virpax Pharmaceuticals extends financing negotiation rights By Investing.com - Investing.com UK
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Canada
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - MarketScreener
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
0.10%
Cap:
|
Volume (24h):